Oncotype DX Breast Cancer test
The intelligent test for early-stage breast cancers
The only genomic test proven to predict a patient’s individual benefit from chemotherapy
For patients with early-stage (I, II, or IIIa), HR (hormone receptor)-positive, HER2-negative breast cancer that is either node-negative or node-positive (1-3 nodes)
The only genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ.
For patients with ductal carcinoma in situ (DCIS) treated by local excision, with or without tamoxifen.
Order a Test
Tests are available through our physician portal. Simply request a specimen kit to submit a sample by calling +1 866-ONCOTYPE (+1 866-662-6897) prior to completing a requisition form on the portal. Once you order, we then work with the pathology team or treating physician to obtain the sample using the specimen kit.How to order the Oncotype DX Breast Recurrence Score® test